Apolipoprotein D: a potential biomarker for cerebral amyloid angiopathy.
Hinke B KuiperijD C HondiusI KerstenA A M VersleijenA J M RozemullerS M GreenbergF H B M SchreuderC J M KlijnM M VerbeekPublished in: Neuropathology and applied neurobiology (2020)
Our data show that apoD is specifically associated with CAA pathology and may be a CSF biomarker for CAA, but clinical application is complicated due to dependency on age, sex and blood-CSF barrier integrity. Well-controlled follow-up studies are required to determine whether apoD can be used as reliable biomarker for CAA.